Loading cancer entity…
Loading cancer entity…
Clinical trials
805 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04814732 | Expanded Access Program of Surufatinib | no longer available | — | — | HutchmedINDUSTRY | 1 | Apr 12, 2024 | clinicaltrials |
| NCT02431715 | 18F-FDOPA PET in Neuroendocrine Tumours | no longer available | — | — | British Columbia Cancer AgencyOTHER | 1 | Feb 21, 2023 | clinicaltrials |
| NCT02174679 |
| 68Ga DOTATATE PET/CT in Neuroendocrine Tumors (Expanded Access) |
| no longer available |
| — |
| — |
| Jonsson Comprehensive Cancer CenterOTHER |
| 1 |
| Jul 27, 2020 |
| clinicaltrials |
| NCT01980732 | 68Ga DOTA-TATE PET/CT in Somatostatin Receptor Positive Tumors | no longer available | — | — | Andrei IagaruOTHER | 1 | Aug 23, 2017 | clinicaltrials |
| NCT02375464 | Gallium-68 DOTATOC for Management of Neuroendocrine Tumors | no longer available | — | — | Northwell HealthOTHER | 0 | Nov 8, 2016 | clinicaltrials |
| NCT02358018 | 68Ga-DOTATOC for Imaging of Neuroendocrine Tumors: Expanded Access Trial | no longer available | — | — | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Nov 2, 2016 | clinicaltrials |
Data updated 22 days agoSource updated Apr 12, 2024source: clinicaltrials